Last updated: 10 April 2024 at 10:06pm EST

Carl Anthony Evans Net Worth




The estimated Net Worth of Carl Anthony Evans is at least 5.35 千$ dollars as of 1 February 2024. Carl Evans owns over 33,333 units of Cns Pharmaceuticals Inc stock worth over 5,353$ and over the last 4 years Carl sold CNSP stock worth over 0$.

Carl Evans CNSP stock SEC Form 4 insiders trading

Carl has made over 1 trades of the Cns Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Carl bought 33,333 units of CNSP stock worth 10,000$ on 1 February 2024.

The largest trade Carl's ever made was buying 33,333 units of Cns Pharmaceuticals Inc stock on 1 February 2024 worth over 10,000$. On average, Carl trades about 5,556 units every 0 days since 2020. As of 1 February 2024 Carl still owns at least 33,458 units of Cns Pharmaceuticals Inc stock.

You can see the complete history of Carl Evans stock trades at the bottom of the page.



What's Carl Evans's mailing address?

Carl's mailing address filed with the SEC is C/O CNS PHARMACEUTICALS, INC., 100 WEST LOOP SOUTH, SUITE 900, HOUSTON, TX, 77027.

Insiders trading at Cns Pharmaceuticals Inc

Over the last 5 years, insiders at Cns Pharmaceuticals Inc have traded over 132,960$ worth of Cns Pharmaceuticals Inc stock and bought 509,021 units worth 458,622$ . The most active insiders traders include Christopher DownsJohn M ClimacoWaldemar Priebe. On average, Cns Pharmaceuticals Inc executives and independent directors trade stock every 79 days with the average trade being worth of 6,051$. The most recent stock trade was executed by Jerzy Gumulka on 1 February 2024, trading 33,333 units of CNSP stock currently worth 10,000$.



What does Cns Pharmaceuticals Inc do?

cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.



Complete history of Carl Evans stock trades at Cns Pharmaceuticals Inc

インサイダー
取引
取引
合計金額
Carl Anthony Evans
ディレクター
購入する 10,000$
1 Feb 2024


Cns Pharmaceuticals Inc executives and stock owners

Cns Pharmaceuticals Inc executives and other stock owners filed with the SEC include: